Pancreatic Cancer

P=N/A, N=5, Recruiting, University Health Network, Toronto

Combining SDUY104 with an ERK inhibitor Ulixertinib produced synergistic antiproliferative activity via enhanced MAPK suppression. In a PANC-1 xenograft model, combination of SDUY104 with BKM-120 exhibited superior antitumor activity compared to either monotherapy. Collectively, this study identifies a potent SHP2 allosteric inhibitor and delineates a critical compensatory signaling mechanism underlying resistance to SHP2-targeted therapy, providing proof-of-concept support for pancreatic cancer treatment.

Notably, AZD3965, a specific MCT1 inhibitor, sensitizes orthotopic PC to PD-1 blockade, effectively inhibiting tumor development...Moreover, activated PSCs secrete CXCL9/CXCL10, which upregulates PD-1 expression in CD8+ T cells via the CXCR3/STAT3 pathway. This study establishes lactate as a crucial TME signaling molecule orchestrating PSC activation and an immunosuppressive microenvironment, providing compelling evidence for combining MCT1 inhibition with immune checkpoint blockade for pancreatic cancer.

The biocompatibility and targeting efficiency of bacterial EVs position them as a novel therapeutic platform for gastrointestinal cancers. This study provides the first preclinical evidence supporting the use of non-pathogenic bacterial exosomes in oncology, highlighting their translational potential for improving treatment outcomes in pancreatic cancer.

Careful surveillance using imaging and tumor markers may facilitate early detection of such aggressive tumors. To our knowledge, this is the first reported case of resectable UC arising from an area of FPPA with fatty replacement.

At 6 months postoperatively, no tumor or hypoglycemia recurrence was observed. This case highlights the importance of considering Doege-Potter syndrome in the differential diagnosis of intra-abdominal tumors that present with hypoglycemic episodes.

NcRNAs play central roles in regulating glycolysis and metabolic adaptation in PDAC and represent promising targets for diagnosis and therapy. Further studies are required to validate key regulatory networks and translate these findings into clinical applications.

P2/3, N=900, Recruiting, AbbVie | Not yet recruiting --> Recruiting

P1, N=58, Active, not recruiting, Boehringer Ingelheim | Trial completion date: Jun 2027 --> Mar 2027 | Trial primary completion date: Jun 2027 --> Mar 2027

P3, N=288, Recruiting, Tianjin Medical University Cancer Institute and Hospital

P2, N=60, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027